

Figure S1: (A) Cell-capture efficacy in a lung cancer cell line (PC9) using the epithelial cell adhesion molecule (EpCAM)-chip at 20 μg/mL and 200 μg/mL base antibody concentrations. (B) Cell-capture efficacy and expression of EpCAM on the surface of lung cancer cell lines detected using flow cytometry. MFI, mean fluorescence intensity.



Figure S2: Representative image of immunohistochemical staining of circulating tumor cells (CTCs) captured using the epithelial cell adhesion molecule (EpCAM)-chip. CK, cytokeratin.



Figure S3: Cancer-specific survival (CSS) and progression-free survival (PFS) according to circulating tumor cell (CTC) count (CTC ≥1/CTC = 0) in (A) patients who received molecular targeted drugs and (B) patients who did not receive molecular targeted drugs.